| Q41318739 | "Awake" ECCO2R superseded intubation in a near-fatal asthma attack |
| Q28192535 | A new insight into aspirin-induced asthma |
| Q46450539 | Active and passive smoking among asthmatic Missourians: implications for health education |
| Q53911863 | Active cigarette smoking and asthma. |
| Q35548946 | Acute Severe Asthma |
| Q92826655 | Acute Severe Asthma in Adolescent and Adult Patients: Current Perspectives on Assessment and Management |
| Q26852173 | Acute lung failure |
| Q43242771 | Acute severe asthma: new approaches to assessment and treatment |
| Q57786327 | An Approach to the Management of High Risk Asthmatic Patients |
| Q37677894 | Analytic review: management of life-threatening asthma in adults |
| Q30238776 | Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future |
| Q28186860 | Aspirin-induced asthma |
| Q28189107 | Aspirin-induced asthma |
| Q50927450 | Aspirin-induced asthma as a risk factor for asthma mortality. |
| Q36225669 | Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital |
| Q51008943 | Bronchial hyperresponsiveness following acute severe asthma. |
| Q35533546 | Case-control study of severe life threatening asthma (SLTA) in adults: demographics, health care, and management of the acute attack |
| Q24805752 | Characteristics and outcome for admissions to adult, general critical care units with acute severe asthma: a secondary analysis of the ICNARC Case Mix Programme Database |
| Q45819144 | Characteristics and outcome for admissions to adult, general critical care units with acute severe asthma: a secondary analysis of the ICNARC Case Mix Programme Database. |
| Q44534206 | Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma |
| Q34036215 | Clinical features and diagnosis of aspirin induced asthma |
| Q40413873 | Clinical features, management, and outcome of patients with severe asthma admitted to the intensive care unit |
| Q53584099 | Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management. |
| Q50758333 | Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations. French prospective study of 169 cases. |
| Q43738554 | Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease |
| Q44453315 | Death due to asthma. New insights into sudden unexpected deaths, but the focus remains on prevention |
| Q74302066 | Decreases in asthma mortality in the United States |
| Q40865581 | Delivering asthma education to special high risk groups |
| Q41365516 | Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study |
| Q35228588 | Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma |
| Q34286702 | Discharge of the asthmatic patient |
| Q74217113 | Dose-response relationships in determining the safety:efficacy ratio |
| Q34159908 | Effects of Smoking Cessation on Airflow Obstruction and Quality of Life in Asthmatic Smokers |
| Q46694299 | Effects of inhaled corticosteroids on the consequences of asthma |
| Q53625416 | Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. |
| Q35537610 | Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma |
| Q34785484 | Elevation of Eosinophil-Derived Neurotoxin in Plasma of the Subjects with Aspirin-Exacerbated Respiratory Disease: A Possible Peripheral Blood Protein Biomarker |
| Q41022620 | Emergent management of acute asthma |
| Q39696984 | Evolving differences in the presentation of severe asthma requiring intensive care unit admission |
| Q37210034 | Experience with use of extracorporeal life support for severe refractory status asthmaticus in children |
| Q37205436 | Factors for poor prognosis of near-fatal asthma after recovery from a life-threatening asthma attack |
| Q44705156 | Fatal or near-fatal asthma: clinical entity or incorrect management? |
| Q33836776 | Genetic mechanisms in aspirin-induced asthma |
| Q34567189 | Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study |
| Q46569254 | Halothane, an effective infrequently used drug, in the treatment of pediatric status asthmaticus: a case report. |
| Q99711834 | High-frequency oscillatory ventilation as a rescue for severe asthma crisis in a child |
| Q37530831 | Immunomodulatory treatments for aspirin exacerbated respiratory disease |
| Q99634788 | Impact of Air Pollution on Asthma Outcomes |
| Q36795403 | Impact of atopy on asthma and allergic rhinitis in the cohort for reality and evolution of adult asthma in Korea. |
| Q36201579 | Impact of smoking on asthma therapy: a critical review of clinical evidence |
| Q28071311 | Inflammatory bowel disease and airway diseases |
| Q35535023 | Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma |
| Q35568521 | Management of the Acute Exacerbation of Asthma |
| Q35058283 | Managing outpatient asthma exacerbations |
| Q84122319 | Managing outpatient asthma exacerbations |
| Q34286718 | Mechanical ventilation in severe asthma |
| Q41534071 | Mechanism of aspirin-induced asthma |
| Q41737153 | Medical and ventilatory management of status asthmaticus |
| Q35573248 | Multicentre observational study of adults with asthma exacerbations: who are the frequent users of the emergency department in Japan? |
| Q28195561 | Natural history and clinical features of aspirin-exacerbated respiratory disease |
| Q41611500 | Natural history and prognosis of advanced lung disease |
| Q42058980 | Near-fatal asthma in South Australia: descriptive features and medication use. |
| Q37352714 | Nicotinic acetylcholine receptor agonist attenuates ILC2-dependent airway hyperreactivity. |
| Q28209835 | Nonsteroidal anti-inflammatory drug-induced reactions and desensitization |
| Q28190284 | Pathogenesis and management of aspirin-intolerant asthma |
| Q37864858 | Pharmacologic approaches to life-threatening asthma |
| Q33776022 | Potential effects of correction of inaccuracies of the mini-Wright peak expiratory flow meter on the use of an asthma self-management plan |
| Q43766164 | Potentially fatal asthma |
| Q43405507 | Potentially fatal asthma and asthma deaths: knowledge is greater but implementation appears problematic |
| Q91775321 | Predicting asthma attacks in primary care: protocol for developing a machine learning-based prediction model |
| Q28165446 | Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland |
| Q35578775 | Profile of Near-Fatal Asthma in an Inner-City Hospital * |
| Q47645992 | Proteomic identification of moesin upon exposure to acrolein |
| Q50747007 | Rates and characteristics of intensive care unit admissions and intubations among asthma-related hospitalizations. |
| Q34620187 | Recommendation for optimal management of severe refractory asthma |
| Q41338673 | Refractory asthma, Part 1: Epidemiology, pathophysiology, pharmacologic interventions |
| Q28188884 | Report of the INTERASMA Working Group on Standardization of Inhalation Provocation Tests in Aspirin-induced Asthma. Oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma |
| Q50883385 | Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. |
| Q37551074 | Risk factors, management and outcomes of patients admitted with near fatal asthma to a tertiary care hospital in Riyadh |
| Q37140629 | Role of biomarkers in understanding and treating children with asthma: towards personalized care |
| Q28177184 | Safety of a specific COX-2 inhibitor in aspirin-induced asthma |
| Q73135740 | Serum ECP and MPO, but not urinary LTE4, are associated with bronchial hyper-responsiveness |
| Q39866659 | Severe or life-threatening asthma exacerbation: patient heterogeneity identified by cluster analysis |
| Q58988936 | Smoking Cessation in Long-Term Conditions: Is There “An Opportunity in Every Difficulty”? |
| Q79330549 | Smoking: a neglected cause of glucocorticoid resistance in asthma |
| Q41436218 | Stabilization of asthma mortality |
| Q28166112 | Subclinical aspirin sensitivity in subjects with nasal polyposis |
| Q24600284 | Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice |
| Q28193348 | Testing for aspirin hypersensitivity |
| Q37166555 | The impact of smoking on clinical and therapeutic effects in asthmatics |
| Q33977226 | The pathobiology of acute asthma |
| Q28193330 | The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients |
| Q35038222 | The pulmonary physician in critical care . 12: Acute severe asthma in the intensive care unit |
| Q73682254 | The role of mucus in fatal asthma |
| Q36834723 | The time delay between drug intake and bronchospasm for nonsteroidal antiinflammatory drugs sensitive patients |
| Q28190530 | The use of analgesics in patients with asthma |
| Q38315108 | Volatile anesthetics for status asthmaticus in pediatric patients: a comprehensive review and case series |
| Q79907716 | [Assessment of quality of care in asthma] |
| Q70785347 | [Prevention of fatal asthma: how to identify the patient at risk?] |
| Q72170391 | [Severe acute asthma in adults] |
| Q81193474 | [What is the therapeutic response to corticosteroid in smokers with asthma?] |